The contribution of complement pathogenic variants and risk polymorphisms in the atypical forms of HUS is very well-established, and screening of the complement genes CFH, MCP, CFI, CFB, C3, and CFHRs in these patients is mandatory (10). This evidence concerns the gene CFB and hemolytic-uremic syndrome.